Li YL, Zhai YF, Zhang HH. Effect of nucleos(t)ide analog antiviral treatment on occurrence of hepatitis B virus-associated hepatocellular carcinoma.
Shijie Huaren Xiaohua Zazhi 2014;
22:5516-5520. [DOI:
10.11569/wcjd.v22.i35.5516]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To explore the effect of nucleos(t)ide analog antiviral treatment on the occurrence of hepatitis B virus (HBV)-associated hepatocellular carcinoma.
METHODS: Two hundred and forty patients diagnosed with chronic hepatitis B at our hospital from December 2009 to December 2013 were divided into an antiviral treatment group and a non-antiviral treatment group. The incidence of liver cancer was compared between the two groups. The effect of cirrhosis on the incidence of liver cancer was also analyzed.
RESULTS: The incidence of liver cancer in the antiviral treatment group was significantly lower than in the non-antiviral treatment group (8.3% vs 17.5%, P < 0.05). The incidence of liver cancer in non-cirrhosis patients receiving antiviral treatment was significantly lower than that in non-cirrhosis patients without antiviral treatment (3.1% vs 20.0%, P < 0.05). There was no difference between cirrhosis patients with and without antiviral treatment (14.3% vs 15.7%, P > 0.05). The incidence of liver cancer in non-cirrhosis HBeAg- patients was significantly higher than that in non-cirrhosis HBeAg+ patients (0.0% vs 9.1%, P < 0.05).
CONCLUSION: Antiviral treatment can effectively reduce the incidence of liver cancer in chronic hepatitis B patients, especially non-cirrhosis HBeAg+ patients.
Collapse